Vir Biotechnology (NASDAQ:VIR – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($1.45) EPS for the quarter, missing the consensus estimate of ($1.21) by ($0.24), Briefing.com reports. The firm had revenue of $3.80 million during the quarter, compared to analyst estimates of $22.39 million. During the same quarter last year, […]
Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year target […]
Vir Biotechnology (NASDAQ:VIR – Free Report) had its target price cut by Barclays from $59.00 to $41.00 in a report released on Friday, MarketBeat.com reports. They currently have an overweight rating on the stock. Several other equities analysts have also weighed in on VIR. Morgan Stanley raised their price objective on shares of Vir Biotechnology […]
Vir Biotechnology (NASDAQ:VIR – Free Report) had its price objective lowered by Needham & Company LLC from $32.00 to $22.00 in a report released on Thursday morning, Benzinga reports. Needham & Company LLC currently has a buy rating on the stock. Other equities research analysts also recently issued reports about the stock. Morgan Stanley boosted […]
Vir Biotechnology (NASDAQ:VIR – Free Report) had its price target cut by Needham & Company LLC from $32.00 to $22.00 in a research note released on Thursday morning, Benzinga reports. The firm currently has a buy rating on the stock. Several other brokerages have also commented on VIR. SVB Securities dropped their price target on […]